Auxilium and Prasco introduce authorized generic version of Testim

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim® (testosterone gel). Prasco has product inventory available and has commenced shipping product. Testim and its Authorized Generic version are testosterone gels approved by the U.S. Food and Drug Administration to treat adult males who have low or no testosterone.

"While Testim has continued to represent an important portion of Auxilium's net sales, we have been proactively planning for this launch in an effort to most strategically position our product franchise to compete in the increasingly crowded and challenging Testosterone Replacement Therapy (TRT) gel market," said Adrian Adams, Chief Executive Officer and President of Auxilium. "We believe the launch of this Authorized Generic of Testim with Prasco could expand the Testim franchise market, build upon our efforts to manage Testim as a mature brand and enable Auxilium to realize maximum shareholder value."

Auxilium will maintain responsibility for the manufacture of Testim and the Authorized Generic testosterone gel, as well as for the distribution of branded Testim.


Auxilium Pharmaceuticals, Inc.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Gel formulation of a new male contraceptive on trial